Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033438 | 0.91 | DRD4 (0.55) | DRD4ACHEHTR1AADRA2CHTR2A | |
| SCHEMBL13033490 | 0.91 | DRD2 (0.55) | DRD4ACHEHTR1AHTR2ADRD2 | |
| SCHEMBL13033469 | 0.89 | KDM4E (0.56) | DRD4ACHEHTR1AHTR2ADRD2 | |
| SCHEMBL13033484 | 0.87 | KDM4E (0.52) | DRD4HTR1AADRA2CDRD2DRD3 | |
| SCHEMBL13033485 | 0.84 | GRIN2B (0.52) | DRD4ACHEDRD2DRD3NPC1 | |
| SCHEMBL13033444 | 0.82 | KDM4E (0.48) | DRD4ACHEHTR1AADRA2CHTR2A | |
| SCHEMBL13033461 | 0.80 | KDM4E (0.46) | DRD4ACHEHTR1AADRA2CHTR2A | |
| SCHEMBL13033473 | 0.80 | DRD4 (0.60) | DRD4DRD2DRD3NPC1GAA | |
| SCHEMBL13033474 | 0.79 | KDM4E (0.56) | DRD4ACHEDRD2DRD3NPC1 | |
| SCHEMBL17969416 | 0.79 | DRD4 (0.49) | DRD4ACHEHTR1AADRA2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286114-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | DRD4 4669/4885ACHE 4747/4885HTR1A 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.